Publikation
Genomic Features of Response to Combination Immunotherapy in Lung Cancer
Wissenschaftlicher Artikel/Review - 14.05.2018
Früh Martin, Peters Solange
Bereiche
PubMed
DOI
Zitation
Früh M, Peters S. Genomic Features of Response to Combination Immunotherapy in Lung Cancer. Cancer Cell 2018; 33:791-793.
Art
Wissenschaftlicher Artikel/Review (Englisch)
Zeitschrift
Cancer Cell 2018; 33
Veröffentlichungsdatum
14.05.2018
eISSN (Online)
1878-3686
Seiten
791-793
Kurzbeschreibung/Zielsetzung
In this issue of Cancer Cell, Hellmann et al. describe in two clinical trials the importance of tumor mutational burden as an independent predictive marker for outcomes with combination nivolumab plus ipilimumab as first-line therapy in metastatic non-small-cell lung cancer and in relapsed small-cell lung cancer.